Description
Indication & Scope
Baraclude® Entecavir Tablets provides long-term antiviral treatment for chronic hepatitis B virus infection in adults and adolescents with compensated liver function and active viral replication.
- Mechanism: Nucleoside reverse transcriptase inhibitor; competitively blocks HBV reverse transcriptase to stop viral DNA synthesis and replication.
- Drug class: Nucleoside analog anti-hepatitis B antiviral agent.
- Clinical use: Long-term suppression of HBV viral load, reduction of liver inflammation, slowing liver fibrosis and cirrhosis progression for chronic hepatitis B patients.
| Generic Name | Entecavir Tablets |
| Brand Name | Baraclude |
| Ingredient | Entecavir |
| Dosage Form | Tablets |
| Package | 0.5mg*7 tablets/box;
1mg*7 tablets/box |
| Conditions Treated | Chronic hepatitis B with persistent viral replication and elevated liver enzymes |
| Taboos | Severe hypersensitivity to entecavir or tablet excipients |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Sealed packs stored at 25°C or below, protected from moisture and high temperature |
| Manufacturer | Sino-American Shanghai Aquib Pharmaceuticals, Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | H20052237; H20080798 |
| Approval Date | Feb 19, 2025 |
| Shelf Life | 36 months |
How to use ?
Recommended Dose: Adults with normal renal function: 0.5mg once daily; lamivudine-resistant cases: 1mg once daily.
Time: Taken on an empty stomach at the same fixed time every day, at least 2 hours before or after meals.
Instructions for use: Swallow whole tablets; never interrupt long-term treatment arbitrarily to avoid viral rebound and drug resistance; monitor HBV DNA and liver function regularly.
Interaction: Renally excreted drugs may alter entecavir clearance when used together; renal function monitoring is required for combined regimens.
Side effects:
1. Common: mild dizziness, fatigue, nausea, transient elevated transaminase.
2. Rare severe: lactic acidosis, severe hepatomegaly with steatosis.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What strict dietary requirement applies to daily administration of Entecavir Tablets for chronic hepatitis B treatment?
Administration must occur on an empty stomach with a two-hour interval before and after meals to ensure sufficient absorption.
What dosage adjustment is required for cases with confirmed lamivudine resistance during Entecavir Tablets long-term hepatitis B therapy?
The daily dosage increases from 0.5mg to 1mg for resistant populations with normal renal function.
What negative outcome will arise from arbitrary premature discontinuation of long-term Entecavir Tablets antiviral therapy?
Sudden treatment stop causes sharp HBV viral rebound, aggravated liver inflammation and accelerated emergence of drug-resistant strains.
Which patient group forms the core applicable population for long-term Entecavir Tablets antiviral intervention?
Adults and adolescents with compensated liver function and active replicating chronic hepatitis B infection.
Baraclude® | Entecavir Tablets | Chronic HBV | DengYueRX
INN: Entecavir Tablets
Indications: Chronic HBV
Dosage Form: Tablets
Strength: 0.5mg/tablet
Original price was: $32.77.$27.86Current price is: $27.86.
Low MOQ
WHO-GMP
Worldwide Delivery
Compliance and Regulatory Documents
Related Products
